Orchestra BioMed
OBIO
43 hedge funds and large institutions have $70.3M invested in Orchestra BioMed in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
10% more funds holding
Funds holding: 39 → 43 (+4)
0.11% more ownership
Funds ownership: 37.2% → 37.31% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
42% less capital invested
Capital invested by funds: $121M → $70.3M (-$51.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$771K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$373K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$251K |
| 4 |
GWMR
GC Wealth Management RIA
Cambridge,
Massachusetts
|
+$151K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$97.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$349K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$278K |
| 3 |
Morgan Stanley
New York
|
-$223K |
| 4 |
State Street
Boston,
Massachusetts
|
-$210K |
| 5 |
BlackRock
New York
|
-$187K |
OBIO Hedge Fund Activity: Q1 2024 in Review
43 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2024, worth a combined $70.3M — down 42% from $121M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new OBIO positions and 1 closed out — a net gain of 4 holders — while 13 added to existing stakes and 17 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $771K. The largest seller was T. Rowe Price Associates, cutting an estimated $349K.
- 43 institutional investors held Orchestra BioMed (OBIO) as of Q1 2024, up from 39 in Q4 2023.
- Funds reported $70.3M of Orchestra BioMed stock for Q1 2024, down 42% quarter-over-quarter.
- 5 funds opened new Orchestra BioMed positions in Q1 2024 and 1 closed out, a net change of +4 holders.
- The largest Orchestra BioMed buyer in Q1 2024 was Perceptive Advisors, an estimated $771K added.
- The largest Orchestra BioMed seller in Q1 2024 was T. Rowe Price Associates, an estimated $349K sold.
Based on aggregated 13F filings for Q1 2024.